EUVIMEDEUVIMED entdecken
Open Access

Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations

Shuntai Zhou iD, Nathan Long, Kyle Rosenke, Michael A Jarvis, Heinz Feldmann iD, Ronald Swanstrom iD

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Shuntai Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lineberger Comprehensive Cancer Center. Hauptthemen laut MEDLINE: Ritonavir, SARS-CoV-2, Hydroxylamines, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of North Carolina (UNC) Center for AIDS Research, National Institute of Allergy and Infectious Diseases, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated the mutation profiles of severe acute respiratory syndrome coronavirus 2 in samples collected from a molnupiravir and nirmatrelvir/ritonavir combination therapy in macaques. We found that molnupiravir induced several nirmatrelvir resistance mutations at low abundance that were not further selected in combination therapy. Coadministration of nirmatrelvir/ritonavir lowered the magnitude of the mutagenetic effect of molnupiravir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirSARS-CoV-2HydroxylaminesAntiviral AgentsDrug Resistance, ViralCytidineMutationCOVID-19 Drug TreatmentLeucineAnimalsProlineDrug Therapy, CombinationUridineIndazolesLactamsNitriles

Stichwörter der Autor:innen

SARS-CoV-2combination therapylethal mutagenesismolnupiravirnirmatrelvir

Substanzen

molnupiravirRitonavirHydroxylaminesAntiviral AgentsCytidinenirmatrelvirLeucineProlineUridineIndazoles

Autor:innen und Institutionen

  • Lineberger Comprehensive Cancer Center.
  • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill.
  • Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana.
  • School of Biomedical Sciences, University of Plymouth.
  • The Vaccine Group Ltd, Plymouth, Devon, United Kingdom.
  • Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill.

ORCID-Profile: Shuntai Zhou, Heinz Feldmann, Ronald Swanstrom

Förderung

  • University of North Carolina (UNC) Center for AIDS Research
  • National Institute of Allergy and Infectious Diseases
  • NCI NIH HHS
  • Intramural Research Program of the
  • NIAID NIH HHS
  • NIH HHS
  • UNC Lineberger Comprehensive Cancer Center
  • National Institutes of Health

Zitieren

APA

Zhou, S., Long, N., Rosenke, K., Jarvis, M. A., Feldmann, H., & Swanstrom, R. (2024). Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae213

Vancouver

Zhou S, Long N, Rosenke K, Jarvis MA, Feldmann H, Swanstrom R. Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae213

BibTeX
@article{Zhou2024,
  author = {Zhou, Shuntai and Long, Nathan and Rosenke, Kyle and Jarvis, Michael A and Feldmann, Heinz and Swanstrom, Ronald},
  title = {Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae213}
}
Kostenlos starten →